The C3 glomerulopathies are a group of rare kidney diseases characterized by complement
dysregulation occurring in the fluid phase and in the glomerular microenvironment, which …

Thrombotic microangiopathy can manifest in a diverse range of diseases and is
characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Studies of complement genetics have changed the landscape of thrombotic
microangiopathies (TMAs), particularly atypical haemolytic uraemic syndrome (aHUS) …

The overall diagnostic yield of massively parallel sequencing–based tests in patients with
chronic kidney disease (CKD) is 30% for paediatric cases and 6–30% for adult cases. These …

Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased
elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we …

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative
brought a diverse panel of experts in glomerular diseases together to discuss the 2012 …

Thrombotic microangiopathy (TMA), a pathological lesion observed in a wide spectrum of
diseases, is triggered by endothelial injury and/or dysfunction. Although TMA lesions are …

Atypical hemolytic uremic syndrome (aHUS), a rare variant of thrombotic microangiopathy, is
characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal …

Glomerulonephritis is a heterogeneous group of disorders that present with a combination of
haematuria, proteinuria, hypertension, and reduction in kidney function to a variable degree …